An object of the present invention is to provide novel pharmaceutical compositions using anti-GRP78 antibodies. More particularly, the present invention aims to provide a novel method of cancer treatment using anti-GRP78 antibodies, novel cell growth inhibitors and anticancer agents that contain anti-GRP78 antibodies, as well as novel anti-GRP78 antibodies. The present inventor attempted to prepare antitumor antibodies that would target GRP78 the localization of which in cancer cells changed to the cell membrane and the inventor successfully obtained an anti-GRP78 antibody that would bind specifically to the cell surface of cancer cells this eventually led to the accomplishment of the above-mentioned objects.
